Literature DB >> 2067207

Beta 2-microglobulin kinetics in end-stage renal failure.

R A Odell1, P Slowiaczek, J E Moran, K Schindhelm.   

Abstract

The kinetics of beta 2-microglobulin (beta 2m) were studied in five anephric or anuric hemodialysis patients. Human beta 2m was isolated from peritoneal dialysate using ion-exchange and gel chromatography and radiolabeled with 125I. Patients were injected with 10 microCi labeled beta 2m. In one study (N = 4), plasma activity was measured over 72 hours. In a second study (N = 4), patients received low-flux dialysis 24 hours after injection and high-clearance dialysis (Bellco BL655) at 48 hours. Plasma activities were fitted to a three-compartment, variable volume model. Endogenous beta 2m levels (radioimmunoassay) were 56 +/- 6 mg/liter. The beta 2m distribution volume was 12.7 +/- 2.0 liter (0.20 +/- 0.03 liter/kg) and the non-renal clearance was 3.0 +/- 0.4 ml/min. The generation rate, 9.9 +/- 1.7 mg/hr (0.16 +/- 0.04 mg/kg/hr), was similar to that measured in subjects with normal renal function. The three compartment model derived from the turnover data gave an adequate fit of the arterial concentrations of endogenous and exogenous beta 2m during low-flux (nil beta 2m clearance) and high-clearance (beta 2m clearance of 19 ml/min) dialysis. Simulations based on this model indicate that extracorporeal treatment can at best remove about 50% of weekly production. These results suggest that beta 2m production is not increased in dialysis patients, that there is substantial non-renal beta 2m clearance, and that the amount of beta 2m that can be removed by extracorporeal therapy is therefore limited.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2067207     DOI: 10.1038/ki.1991.114

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  14 in total

Review 1.  Once upon a time in dialysis: the last days of Kt/V?

Authors:  Raymond Vanholder; Griet Glorieux; Sunny Eloot
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 2.  Home haemodialysis and uraemic toxin removal: does a happy marriage exist?

Authors:  Raymond Vanholder; Sunny Eloot; Nathalie Neirynck; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

3.  High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.

Authors:  Francisco Maduell; Francesc Moreso; Mercedes Pons; Rosa Ramos; Josep Mora-Macià; Jordi Carreras; Jordi Soler; Ferran Torres; Josep M Campistol; Alberto Martinez-Castelao
Journal:  J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 10.121

Review 4.  An update on uremic toxins.

Authors:  N Neirynck; R Vanholder; E Schepers; S Eloot; A Pletinck; G Glorieux
Journal:  Int Urol Nephrol       Date:  2012-08-15       Impact factor: 2.370

Review 5.  Beta-2 Microglobulin Amyloidosis: Past, Present, and Future.

Authors:  Ignacio Portales-Castillo; Jerry Yee; Hiroshi Tanaka; Andrew Z Fenves
Journal:  Kidney360       Date:  2020-10-21

6.  Residual Function Effectively Controls Plasma Concentrations of Secreted Solutes in Patients on Twice Weekly Hemodialysis.

Authors:  Sheldon C Leong; Justin N Sao; Abigail Taussig; Natalie S Plummer; Timothy W Meyer; Tammy L Sirich
Journal:  J Am Soc Nephrol       Date:  2018-05-04       Impact factor: 10.121

7.  Protein-bound solute removal during extended multipass versus standard hemodialysis.

Authors:  Sunny Eloot; Wim Van Biesen; Mette Axelsen; Griet Glorieux; Robert Smith Pedersen; James Goya Heaf
Journal:  BMC Nephrol       Date:  2015-04-18       Impact factor: 2.388

Review 8.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

Review 9.  Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico.

Authors:  Maria Eleni Roumelioti; Thomas Nolin; Mark L Unruh; Christos Argyropoulos
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

10.  Multipass haemodialysis: a novel dialysis modality.

Authors:  James Goya Heaf; Mette Axelsen; Robert Smith Pedersen
Journal:  Nephrol Dial Transplant       Date:  2012-11-07       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.